Gamboa-López GJ, Bolado-García PB, Álvarez-Nemegyei J

Language: Spanish
References: 12
Page: 477-480
PDF size: 150.23 Kb.

ABSTRACT

Background: carbetocin, a potentially cardio toxic drug is used by intravenous bolus for uterine bleeding prevention during cesarean section. The aim was to assess the cardiac effects of carbetocin in patients undergoing cesarean sections.
Methods: a pretest-postest design study was carried out on 74 women (23 ± 5.3 years, ASA I-II classification, no history of pregnant induced-hypertension) who underwent elective or emergency cesarean section. At surgical room entry (baseline), and after administration of carbetocin (infunded 100 µg along 30 minutes) during the anesthesic-surgical follow up, vital signs and EKG were registered; and CK, CK MB, and troponin I blood levels were measured. Wilcoxon´s rank test was used.
Results: significant changes were found on CK (30 vs. 58), CK MB (4.0 vs. 5.9), troponin I (0.01 vs. 0.03), blood sistolic pressure (110 vs. 100), blood diastolic pressure (70 vs. 60) and heart rate (76 vs. 90); all of them: p ‹ 0.001. However, no patient showed heart ischemia signs during the EKG monitorization.
Conclusions: an increase on biochemical indicators of myocardic damage blood levels was observed after the administration of a carbetocin bolus in patients underwent cesarean section.

REFERENCES

1. Leung SW, Nq PS, Wong WY, Cheung TH. A randomised trial of carbetocin versus syntometrine in the management of the third stage of labour. Br J Obstet Gynaecol 2006;113(2):1459-1464. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1804104/

2. Ross RM, Baker T. Cardiac enzymes in patients undergoing caesarean section. Can J Anaesth 1995;42(1):46-50.

3. Mukaddam-Daher S, Jankowski M, Wang D, Menaouar A, Gutkowska J. Regulation of cardiac oxytocin system and natriuretic peptide during rat gestation and pospartum. J Endocrinol 2002;175(1)211:216. Disponible en http://joe.endocrinology-journals.org/content/175/1/211.long

4. Jankowski M, Danalache B, Wang D, Bhat P, Hajjar F, Marcinkiewicz M, et al. Oxytocin in cardiac ontogeny. Proc Natl Acad Sci 2004;101(35):1374-1379. Epub 2004 Aug 17. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC516519/

5. Borruto F, Treisser A, Comparetto C. Utilization of carbetocin for prevention of pospartum hemorrhage after cesarean section: a randomized clinical trial. Arch Gynecol Obstet 2009;280(5):707-712. Epub 2009 Feb 20.

6. Chong YS, Su LL, Arulkumaran S. Current strategies for the prevention of pospartum haemorrhage in the third stage of labour. Curr Opin Obstet Gynecol 2004;16(2)143:150.

7. Peters N. Duvekot JJ. Carbetocin for the prevention of pospartum hemorrhage: a systematic review. Obstet Gynecol Surv 2009;64(2):129:135.

8. den Hertog CEC, de Groot ANJA, van Dongen PWJ. Historia y uso de los oxitócicos. [Edición española]. Eur J Obstet Gynecol Reprod Biol 2001;1(4):315-319. Disponible en http://www.elmedicointeractivo.com/ap1/emiold/.../315-319.pdf

9. Balki M, Ronayne M, Davies S, Fallah S, Kingdom J, Windrim R, et al. Minimum oxytocin dose requirement after cesarean delivery for labor arrest. Obstet Gynecol 2006;107(1):45:50.

10. Carvalho J, Balki M, Kingdom J, Windrim R, Oxytocin requirements at elective cesarean delivery: a dose-finding study. Obstet Gynecol 2004;104(5 pt 1);1005-1010.

11. Thomas JS, Koh SH, Cooper GM. Haemodynamic effects of oxytocin given as i.v. bolus or infusion on women undergoing caesarean section. Br J Anaesth 2006;98(1):116-119.

12. Gregory AL. Maternal hemodynamics after oxytocin bolus compared with infusion in the third stage of labor: a randomized controlled trial. Br J Anaesth 2007;98(1):116-119.